Loading clinical trials...
Loading clinical trials...
The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients ------ Risk Early Warning and Follow-up Study
Conditions
Interventions
serum AKR1B10 levels
Locations
1
China
University of South China
Hengyang, Hunan, China
Start Date
May 16, 2025
Primary Completion Date
March 31, 2028
Completion Date
March 31, 2028
Last Updated
August 29, 2025
NCT07439939
NCT05597488
NCT06680583
NCT07469319
NCT07471542
NCT06932783
Lead Sponsor
The First Affiliated Hospital of University of South China
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions